Management of endocrine resistant breast cancer
| Autor: | S. Sundar, Kenneth J. O'Byrne, Marios P. Decatris |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
medicine.medical_specialty Combination therapy medicine.medical_treatment Antineoplastic Agents Breast Neoplasms Vinorelbine Targeted therapy Breast cancer Trastuzumab Internal medicine medicine Humans Anthracyclines Neoplasm Metastasis skin and connective tissue diseases business.industry Obstetrics and Gynecology Cancer medicine.disease Metastatic breast cancer Drug Resistance Neoplasm Female Hormone therapy business medicine.drug |
| Zdroj: | The journal of the British Menopause Society. 10(1) |
| ISSN: | 1362-1807 |
| Popis: | Metastatic breast cancer (MBC) may present de novo but more commonly develops in women initially presenting with early breast cancer despite the widespread use of adjuvant hormonal and cytotoxic chemotherapy. MBC is incurable. Hormone sensitive MBC eventually becomes resistant to endocrine therapy in most women. Anthracyclines are the agents of choice in the treatment of endocrine resistant MBC. With the widespread use of anthracyclines in the adjuvant setting, taxanes have become the agents of choice for many patients. Recently capecitabine has become established as a standard of care for patients pretreated with anthracyclines and taxanes. However, a range of agents have activity as third line treatment. These include gemcitabine, vinorelbine and platinum analogues. The sequential use of non-cross resistant single agents rather than combination therapy is preferable in most women with MBC. Even though combination therapy can improve response rates and increase progression free interval, there is no robust evidence to indicate an advantage in terms of overall survival. Moreover, combination therapy is associated with a higher toxicity rate and poor quality of life. There is no role for dose-intense therapy, high dose therapy or maintenance chemotherapy outside the context of a clinical trial. The introduction of trastuzumab, monoclonal antibody targeting growth factor receptors, has improved the therapeutic options for women with tumours overexpressing HER2/neu. DNA micro-array profiles of tumours can potentially help to individualise therapy in future. Molecular targeted therapy has the potential to revolutionise the management of MBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|